Receptor Life Sciences Names Successful Pharmaceutical Industry Executive, Mark Theeuwes, President and Chief Executive Officer

SEATTLE--(BUSINESS WIRE)--Receptor Life Sciences (“RLS”) today announced the appointment of Mark Theeuwes as President, Chief Executive Officer and member of the Board of Directors of RLS. Mr. Theeuwes will succeed Greg Wesner, who co-founded Receptor in 2015 and has served as CEO and Director since its inception. Mr. Wesner will remain on the Board of Directors of RLS.

“RLS is at an important inflection point with our delivery technologies expected to have INDs in 2021. Mark is an experienced pharmaceutical executive with a proven track record of building clinical and commercial stage organizations. Under Mark’s leadership, RLS is well-positioned for continued success,” said Arthur Rubinfeld, Executive Chairman of RLS.

Mr. Theeuwes joins RLS following the acquisition of Engage Therapeutics (“Engage”) by UCB in June 2020. He served as Chief Operating Officer from 2018 until its acquisition, which came following positive data from a large, randomized Phase 2 clinical trial of its lead product candidate in development for a new product category called REST (Rapid Epileptic Seizure Termination). Prior to joining Engage, Mr. Theeuwes held positions of increasing responsibility at Egalet, NPS (acquired by Shire), ViroPharma (acquired by Shire), OraPharma (acquired by Valeant), Johnson & Johnson and Alza (acquired by J&J).

“I am honored and excited to lead RLS and build upon the solid foundation that Greg and the team have established over the last five years,” said Mr. Theeuwes. “Receptor has two promising clinical candidates in its pipeline that may favorably impact millions of patients who today have inadequate therapies. I look forward to progressing the pipeline to bring these therapies to patients in need.”

About Receptor Life Sciences

Receptor Life Sciences is a pharmaceutical company that applies FDA-approved drug-delivery technologies to develop innovative therapies to address central nervous system disorders that have few safe and effective treatments. Receptor Life Sciences uses these technologies to produce inhaled and oral cannabinoid products that hold the potential to provide precision, consistency, reliability, and convenience. For more information about Receptor Life Sciences, its patented product candidates and its progress toward FDA approval see: www.ReceptorLife.com.

Mark Theeuwes
mtheeuwes@receptorlife.com